Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats

开发和验证一种新型即时护理技术，用于快速非靶向识别新出现的阿片类药物和其他药物威胁

• 批准号: 10775250
• 负责人: Drew Alexander Hall
• 金额: $ 64.03万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10775250
• 关键词: Address; American; Anesthetics; Applied Research; Authorization documentation; Automobile Driving; Benzodiazepines; Biological Assay; Biosensor; COVID-19; Canada; Cities; Client; Cocaine; Complex; Country; Development; Disease Outbreaks; Drug Controls; Drug usage; Drug user; Effectiveness; Epidemic; Exercise; Federal Government; Fentanyl; Forensic Medicine; Grant; Health; Heroin; Human; Improve Access; Individual; Intervention; Investigation; Ketamine; Legal; Machine Learning; Marketing; Mass Spectrum Analysis; Medical Examiners; Methamphetamine; Morphine; Nature; Norfentanyl; North America; Opioid; Overdose; Overdose reduction; Overdose reversal; Performance; Persons; Pharmaceutical Preparations; Plasma; Point of Care Technology; Point-of-Care Systems; Policies; Population; Populations at Risk; Psychotropic Drugs; Quality-Adjusted Life Years; Research Infrastructure; Risk; Risk Behaviors; Sampling; Services; Specimen; Spectroscopy, Fourier Transform Infrared; Stimulant; System; Technical Expertise; Technology; Testing; Time; United States; Urine; Validation; Work; assay development; authority; carfentanil; cost; detection method; drug market; ecstasy; experience; high risk; instrument; interest; machine learning algorithm; meetings; mortality; multidisciplinary; new technology; novel; overdose prevention; overdose risk; point of care; prevent; preventive intervention; public health emergency; reagent testing; repository; scale up; service providers; substance use; synthetic opioid; technology development; test strip; tool

ABSTRACT The North American overdose crisis remains at epidemic levels, with over 1 million lives lost over the past decade. This crisis is primarily driven by the emergence of high- potency opioids such as fentanyl, in unregulated (“street”) drug markets. However, the volatility of these markets has also led to the emergence of other even more potent opioids such as carfentanil and nitazene-class opioids, along with adulterants such as benzodiazepines. These emerging drug threats produce complex overdose presentations and difficulties in overdose reversal, all of which contribute to overdose mortality. Drug checking services, which provide individuals with analytic information regarding the presence of compounds in drugs of unknown composition, are increasingly employed in North America to prevent overdose mortality during the era of high-potency synthetic opioid contamination. However, current efforts to implement and expand access to drug checking services are hampered, primarily because current available technologies have logistical, technical, and cost-related barriers that impede their feasibility as point-of-care interventions. This is exacerbated by the need for ongoing assay development to ensure that drug checking technologies can continue to accurately detect and identify novel high-potency drug threats in North American drug markets. Meeting these needs is critical to advance the effectiveness of drug checking at the population level, particularly for drug checking service providers, individuals who use drugs, and medical examiners undertaking forensic investigations of overdose mortality. The aim of the current project is therefore to develop and validate a novel point-of-care technology, known as DoseCheck, for rapid non-targeted identification of emerging drug threats. Specifically, we will: 1) validate the DoseCheck system’s capacity to differentiate between and within classes of opioid, stimulant, depressant, and anesthetic compounds in non-targeted analyses of unregulated drugs; 2) undertake timed exercises to evaluate the capacity of our team to rapidly adapt the DoseCheck system to detect and differentiate a novel emerging drug threat; and 3) test the capacity of the DoseCheck system to identify and differentiate distinct opioid metabolites within human biomatrices. Achieving these aims will generate high impact and highly translational findings that will support the expansion of adaptive, analytically sophisticated, and low-cost point-of-care drug checking services and thereby contribute to a reduction in overdose mortality.

抽象的 北美过量危机仍处于流行病上，生命超过100万 在过去的十年中迷失了。这场危机主要是由高级出现的驱动 在不受监管（“街道”）药物市场中的芬太尼等效力阿片类药物。但是， 这些市场的波动也导致了其他更有效的出现 诸如Carfentanil和Nitazene级的绿核酸等烯类类烯型烯类烯以及掺假剂，例如 苯二氮卓。这些新兴的毒品威胁会产生复杂的过量 过量逆转的演示和困难，所有这些都导致过量 死亡。药物检查服务，为个人提供分析信息 关于未知组成药物中化合物的存在，越来越多 在北美工作，以防止高剂量的过量死亡率 合成阿片类药物污染。但是，目前实施和扩展的努力 访问药物检查服务受到阻碍，主要是因为当前可用 技术具有后勤，技术和成本相关的障碍，这些障碍阻碍了他们的 可行性作为护理点的干预措施。这对持续的需求加剧了这一点 测定开发以确保药物检查技术可以继续 准确检测并识别北美药物中新型的高效药物威胁 市场。满足这些需求对于提高药物检查的有效性至关重要 人口水平，特别是对于药物检查服务提供者，使用的个人 药物和体检医师正在对过量死亡率进行法医调查。 因此，当前项目的目的是开发和验证一个新的护理点 技术，即Dosecheck，用于快速对新兴药物的非目标识别 威胁。特别是，我们将：1）验证Dosecheck系统区分的能力 阿片类药物，刺激性，抑郁剂和麻醉化合物之间和内部和内部 在不受监管的药物的非目标分析中； 2）进行定时练习以评估 我们团队能够快速调整Dosecheck系统以检测和 区分新的新兴毒品威胁； 3）测试Dosecheck的能力 识别和区分人类生物植物中不同阿片代谢产物的系统。 实现这些目标将产生高影响力和高度翻译的发现 支持自适应，分析复杂和低成本的体现的扩展 药物检查服务，从而有助于降低过量死亡率。